Experiment Overview
| Repository ID: | FR-FCM-Z638 | Experiment name: | immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer | MIFlowCyt score: | 51.50% |
| Primary researcher: | Yoshinobu Koguchi | PI/manager: | Yoshinobu Koguchi | Uploaded by: | Yoshinobu Koguchi |
| Experiment dates: | 2016-05-11 - 2019-05-30 | Dataset uploaded: | Feb 2023 | Last updated: | Apr 2023 |
| Keywords: | [immunotherapy] [pembrolizumab] [chemotherapy] [paclitaxel] [capecitabine] [triple-negative breast cancer] [programmed death 1] [lymphodepletion] | Manuscripts: | |||
| Organizations: |
Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR (United States)
|
||||
| Purpose: | Flow cytometry were used to explore univariate associations of baseline peripheral blood immune profile with week 12 overall response. | ||||
| Conclusion: | Pembrolizumab with paclitaxel or capecitabine is safe and clinically active. Both regimens were lymphodepleting, highlighting the competing immunostimulatory versus lymphotoxic effects of cytotoxic chemotherapy. | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | CD-Chex Plus was used to ensure frequencies of major cell populations of interests fall into mean+/- 3SD in the Levey-Jennings plots. | ||||
